This work was supported by the National Science Foundation for Outstanding Young Scholars of China (No. 82122028 to LX), the National Natural Science Foundation of China (No. 82173094 to LX), Natural Science Foundation of Chong Qing (No. 2023NSCQ-BHX0087 to SW).

The C57BL/6J mice (referred to B6 mice) and naive P14 transgenic mice9,27 used were 6-10 weeks of age weighing 18-22 g. Both male and female were included without randomization or blinding. All animal studies were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Qingdao Agricultural University.
1. Preparation of medium and reagents
<ol>
	<li>Prepare B16F10-GP melan...

Evaluating Antigen-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells During Lymph Node Metastasis

<ol>
	<li>Morad, G., Helmink, B. A., Sharma, P., Wargo, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hallmarks+of+response,+resistance,+and+toxicity+to+immune+checkpoint+blockade.">Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.</a> Cell. 184 (21), 5309-5337 (2021).</li><li>Korman, A. J., Garrett-Thomson, S. C., Lonberg, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+foundations+of+immune+checkpoint+blockade+and+the+ipilimumab+approval+decennial.">The foundations of immune checkpoint blockade and the ipilimumab approval decennial.</a> Nat Rev Drug Discov. 21 (7), 509-528 (2022).</li><li>Chamoto, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mitochondrial+activation+chemicals+synergize+with+surface+receptor+PD-1+blockade+for+T+cell-dependent+antitumor+activity.">Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity.</a> Proc Natl Acad Sci U S A. 114 (5), E761-E770 (2017).</li><li>Spitzer, M. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Systemic+immunity+is+required+for+effective+cancer+immunotherapy.">Systemic immunity is required for effective cancer immunotherapy.</a> Cell. 168 (3), 487-502 (2017).</li><li>Yost, K. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Clonal+replacement+of+tumor-specific+T+cells+following+PD-1+blockade.">Clonal replacement of tumor-specific T cells following PD-1 blockade.</a> Nat Med. 25 (8), 1251-1259 (2019).</li><li>Wu, T. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Peripheral+T+cell+expansion+predicts+tumour+infiltration+and+clinical+response.">Peripheral T cell expansion predicts tumour infiltration and clinical response.</a> Nature. 579 (7798), 274-278 (2020).</li><li>Connolly, K. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+reservoir+of+stem-like+cd8(+)+t+cells+in+the+tumor-draining+lymph+node+preserves+the+ongoing+antitumor+immune+response.">A reservoir of stem-like cd8(+) t cells in the tumor-draining lymph node preserves the ongoing antitumor immune response.</a> Sci Immunol. 6 (64), eabg7836 (2021).</li><li>Schenkel, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Conventional+type+I+dendritic+cells+maintain+a+reservoir+of+proliferative+tumor-antigen+specific+Tcf-1++CD8++T+cells+in+tumor-draining+lymph+nodes.">Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific Tcf-1+ CD8+ T cells in tumor-draining lymph nodes.</a> Immunity. 54 (10), 2338-2353 (2021).</li><li>Huang, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+primordial+differentiation+of+tumor-specific+memory+cd8(+)+t+cells+as+bona+fide+responders+to+pd-1/pd-l1+blockade+in+draining+lymph+nodes.">The primordial differentiation of tumor-specific memory cd8(+) t cells as bona fide responders to pd-1/pd-l1 blockade in draining lymph nodes.</a> Cell. 185 (22), 4049-4066 (2022).</li><li>Kanda, Y., Okazaki, T., Katakai, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Motility+dynamics+of+T+cells+in+tumor-draining+lymph+nodes:+A+rational+indicator+of+antitumor+response+and+immune+checkpoint+blockade.">Motility dynamics of T cells in tumor-draining lymph nodes: A rational indicator of antitumor response and immune checkpoint blockade.</a> Cancers (Basel). 13 (18), 4616 (2021).</li><li>Karaman, S., Detmar, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mechanisms+of+lymphatic+metastasis.">Mechanisms of lymphatic metastasis.</a> J Clin Invest. 124 (3), 922-928 (2014).</li><li>Pereira, E. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lymph+node+metastases+can+invade+local+blood+vessels,+exit+the+node,+and+colonize+distant+organs+in+mice.">Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice.</a> Science. 359 (6382), 1403-1407 (2018).</li><li>Brown, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lymph+node+blood+vessels+provide+exit+routes+for+metastatic+tumor+cell+dissemination+in+mice.">Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice.</a> Science. 359 (6382), 1408-1411 (2018).</li><li>Reticker-Flynn, N. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lymph+node+colonization+induces+tumor-immune+tolerance+to+promote+distant+metastasis.">Lymph node colonization induces tumor-immune tolerance to promote distant metastasis.</a> Cell. 185 (11), 1924-1942 (2022).</li><li>Leong, S. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Impact+of+nodal+status+and+tumor+burden+in+sentinel+lymph+nodes+on+the+clinical+outcomes+of+cancer+patients.">Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients.</a> J Surg Oncol. 103 (6), 518-530 (2011).</li><li>Lyman, G. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Sentinel+lymph+node+biopsy+for+patients+with+early-stage+breast+cancer:+American+society+of+clinical+oncology+clinical+practice+guideline+update.">Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update.</a> J Clin Oncol. 35 (5), 561-564 (2017).</li><li>Wong, S. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Sentinel+lymph+node+biopsy+and+management+of+regional+lymph+nodes+in+melanoma:+American+society+of+clinical+oncology+and+society+of+surgical+oncology+clinical+practice+guideline+update.">Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update.</a> Ann Surg Oncol. 25 (2), 356-377 (2018).</li><li>Faries, M. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Completion+dissection+or+observation+for+sentinel-node+metastasis+in+melanoma.">Completion dissection or observation for sentinel-node metastasis in melanoma.</a> N Engl J Med. 376 (23), 2211-2222 (2017).</li><li>Giuliano, A. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effect+of+axillary+dissection+vs+no+axillary+dissection+on+10-year+overall+survival+among+women+with+invasive+breast+cancer+and+sentinel+node+metastasis:+The+ACOSOG+Z0011+(alliance)+randomized+clinical+trial.">Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (alliance) randomized clinical trial.</a> JAMA. 318 (10), 918-926 (2017).</li><li>du Bois, H., Heim, T. A., Lund, A. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor-draining+lymph+nodes:+At+the+crossroads+of+metastasis+and+immunity.">Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.</a> Sci Immunol. 6 (63), eabg3551 (2021).</li><li>An, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Locally+trapping+the+c-c+chemokine+receptor+type+7+by+gene+delivery+nanoparticle+inhibits+lymphatic+metastasis+prior+to+tumor+resection.">Locally trapping the c-c chemokine receptor type 7 by gene delivery nanoparticle inhibits lymphatic metastasis prior to tumor resection.</a> Small. 15 (9), e1805182 (2019).</li><li>Lee, C. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor+metastasis+to+lymph+nodes+requires+yap-dependent+metabolic+adaptation.">Tumor metastasis to lymph nodes requires yap-dependent metabolic adaptation.</a> Science. 363 (6427), 644-649 (2019).</li><li>Buchwald, Z. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor-draining+lymph+node+is+important+for+a+robust+abscopal+effect+stimulated+by+radiotherapy.">Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy.</a> J ImmunoTher Cancer. 8 (2), e000867 (2020).</li><li>Siddiqui, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intratumoral+Tcf1+PD-1+CD8++T+cells+with+stem-like+properties+promote+tumor+control+in+response+to+vaccination+and+checkpoint+blockade+immunotherapy.">Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy.</a> Immunity. 50 (1), 195.e10-211.e10 (2019).</li><li>Ashton-Rickardt, P. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Evidence+for+a+differential+avidity+model+of+T+cell+selection+in+the+thymus.">Evidence for a differential avidity model of T cell selection in the thymus.</a> Cell. 76 (4), 651-663 (1994).</li><li>Manjunath, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effector+differentiation+is+not+prerequisite+for+generation+of+memory+cytotoxic+T+lymphocytes.">Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes.</a> J Clin Invest. 108 (6), 871-878 (2001).</li><li>Khan, O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=TOX+transcriptionally+and+epigenetically+programs+CD8++T+cell+exhaustion.">TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion.</a> Nature. 571 (7764), 211-218 (2019).</li><li>North, R. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cyclophosphamide-facilitated+adoptive+immunotherapy+of+an+established+tumor+depends+on+elimination+of+tumor-induced+suppressor+T+cells.">Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.</a> J Exp Med. 155 (4), 1063-1074 (1982).</li><li>Maine, G. N., Mule, J. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Making+room+for+T+cells.">Making room for T cells.</a> J Clin Invest. 110 (2), 157-159 (2002).</li><li>Xue, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Adoptive+cell+therapy+with+tumor-specific+th9+cells+induces+viral+mimicry+to+eliminate+antigen-loss-variant+tumor+cells.">Adoptive cell therapy with tumor-specific th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells.</a> Cancer Cell. 39 (12), 1610.e9-1622.e9 (2021).</li><li>Prokhnevska, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CD8++T+cell+activation+in+cancer+comprises+an+initial+activation+phase+in+lymph+nodes+followed+by+effector+differentiation+within+the+tumor.">CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor.</a> Immunity. 56 (1), 107.e5-124.e5 (2023).</li><li>Wang, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor+transplantation+for+assessing+the+dynamics+of+tumor-infiltrating+CD8++T+cells+in+mice.">Tumor transplantation for assessing the dynamics of tumor-infiltrating CD8+ T cells in mice.</a> J Vis Exp. (172), e62442 (2021).</li><li>Liu, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor-specific+memory+cd8(+)+t+cells+are+strictly+resident+in+draining+lymph+nodes+during+tumorigenesis.">Tumor-specific memory cd8(+) t cells are strictly resident in draining lymph nodes during tumorigenesis.</a> Cell Mol Immunol. 20 (4), 423-426 (2023).</li><li>Fransen, M. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor-draining+lymph+nodes+are+pivotal+in+pd-1/pd-l1+checkpoint+therapy.">Tumor-draining lymph nodes are pivotal in pd-1/pd-l1 checkpoint therapy.</a> JCI Insight. 3 (23), e124507 (2018).</li><li>Francis, D. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Blockade+of+immune+checkpoints+in+lymph+nodes+through+locoregional+delivery+augments+cancer+immunotherapy.">Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy.</a> Sci Transl Med. 12 (563), eaay3575 (2020).</li><li>Garner, H., de Visser, K. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immune+crosstalk+in+cancer+progression+and+metastatic+spread:+A+complex+conversation.">Immune crosstalk in cancer progression and metastatic spread: A complex conversation.</a> Nat Rev Immunol. 20 (8), 483-497 (2020).</li></ol>

During tumorigenesis, antigen-presenting cells (APCs) engulf tumor antigens and migrate to TdLN where they prime CD8+ T cells. After priming and activation, CD8+ T cells leave the TdLN and infiltrate the tumor to kill tumor cells10. Through TdLN resection and the administration of FTY720 which block the exit of immune cells from the lymphoid organs, several studies have demonstrated the pivotal role of TdLN in ensuring the efficacy of PD-1/PD-L1 checkpoint therapy<sup class="...

Cancer immunotherapy, especially the immune checkpoint blockade (ICB), has revolutionized cancer therapy1. ICB blocks the coinhibitory immunoreceptors (such as PD-1, Tim-3, LAG-3, and TIGIT), which are highly expressed in exhausted CD8+ T cells in the tumor microenvironment (TME), leading to the reinvigoration of exhausted CD8+ T cells2. Considering the heterogeneity of exhausted CD8+ T cells, accumulating evidence revealed that tumor-specific CD8+ T cells derived from the periphery, including draining lymph node (dLN), but not in TME, mediate the efficacy of ICB3,4,5,6,7,8. Recently, TdLN derived TCF-1+TOX- tumor-specific memory CD8+ T cells (TdLN-TTSM) was confirmed to be the genuine responders to ICB which embody several functional properties of conventional memory T cells and could further expand and differentiate into progeny exhausted cells upon ICB treatment9. Altogether, these findings corroborated the importance of LN in mounting anti-tumor immunity.
Lymph node functions as a critical place in facilitating the priming and activation of tumor-specific CD8+ T cells by providing structural basis as well as biological signals10. Several types of cancer cells frequently seed sentinel lymph node (SLN, the first LN draining a primary tumor) before systematic dissemination11. The presence of SLN metastasis is linked with poor outcome in human cancer and preclinical models showed that tumor cells in TdLN could spread to distant organs through both the lymphatic vessels and blood vessels of the node12,13,14,15. SLN biopsy now represents a standard procedure to guide subsequent treatment decisions in many solid tumor types which could avoid unnecessary resection of uninvolved LN16,17. Even to the involved LN, it remains controversial whether and when surgical resection is needed as several studies have demonstrated that the removal of regional LN did not exhibit improved overall survival compared to those that received radiation or systemic therapy without regional LN resection18,19. One interpretation is that metastatic LN (mLN) with microscopic disease may retain some capacity to educate immune cells and provide some therapeutic benefits. So, it is critically important to elucidate how LN metastasis affects the anti-tumor immune response, especially the properties and functions of TdLN-TTSM.
Until now, both preclinical and clinical data have revealed some structural and cellular alterations in mLN20. However, the dynamic changes of tumor-specific CD8+ T cells during LN metastasis have not been delineated. Therefore, developing a compelling model of LN metastasis is needed for further investigation. Indeed, several studies have reported mLN mouse models through different ways14,21,22. For example, spontaneous metastasis in axillary LNs was conducted through the implantation of 4T1 breast cancer cells into the mammary fat pad22. In another study, Reticker-Flynn et al. generated melanoma cell lines with high incidence of spread from subcutaneous primary tumor to LNs through serial inoculation of tumor cells cultured from dissociated mLN tissues (nine rounds)14. Another commonly used model was prepared by the injection of tumor cells into the footpad and the metastatic loci would be formed in popliteal LN22. Notably, it is difficult to evaluate the precise timepoints of intervention because LN metastasis in these models is not always faithful.
In the present study, a murine LN metastatic model was established through the intranodal injection of B16F10-GP cells23,24, generated by CRISPR/Cas9-mediated insertion of LCMV virus glycoprotein (GP) gene sequence into the genome of B16F10 cell line9. Then, these mice were transferred with P14 cells which harbor transgenic T cell receptors (TCRs) specifically recognize the H-2Db GP33-41 epitope25,26 and the systemic and local dynamics of antigen-specific CD8+ T cells during LN metastasis could be investigated. Our experimental design provides a useful model for the study of immune responses, especially the antigen-specific CD8+ T cells during the LN metastasis which excludes the perturbation of bystander CD8+ T cells. These results would affect the clinical treatment options of whether to remove or retain the mLN and shed new light on the manipulation of mLN to achieve maximum therapeutic benefits.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>1.5 mL centrifuge tube</td>
			<td>KIRGEN</td>
			<td>KG2211</td>
			<td></td>
		</tr>
		<tr>
			<td>100 U insulin syringe</td>
			<td>BD Biosciences&#160;</td>
			<td>320310</td>
			<td></td>
		</tr>
		<tr>
			<td>15 mL conical tube&#160;</td>
			<td>BEAVER&#160;</td>
			<td>43008</td>
			<td></td>
		</tr>
		<tr>
			<td>2,2,2-Tribromoethanol (Avertin)&#160;</td>
			<td>Sigma&#160;</td>
			<td>T48402-25G&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>2-Methyl-2-butanol</td>
			<td>Sigma</td>
			<td>240486-100ML&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>70 &#956;m nylon cell strainer</td>
			<td>BD Falcon&#160;</td>
			<td>352350</td>
			<td></td>
		</tr>
		<tr>
			<td>APC anti-mouse CD45.1&#160;</td>
			<td>BioLegend&#160;</td>
			<td>110714</td>
			<td>Clone:A20&#160;</td>
		</tr>
		<tr>
			<td>B16-GP cell line</td>
			<td>Beijing Biocytogen Co.Ltd, China</td>
			<td>Custom</td>
			<td></td>
		</tr>
		<tr>
			<td>BSA-V (bovine serum albumin)&#160;</td>
			<td>Bioss</td>
			<td>bs-0292P</td>
			<td></td>
		</tr>
		<tr>
			<td>cell culture dish</td>
			<td>BEAVER&#160;</td>
			<td>43701/43702/43703&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>centrifuge</td>
			<td>Eppendorf</td>
			<td>5810R-A462/5424R&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>cyclophosphamide</td>
			<td>Sigma&#160;</td>
			<td>C0768-25G&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>Cyclophosphamide (CTX)</td>
			<td>Sigma</td>
			<td>PHR1404</td>
			<td></td>
		</tr>
		<tr>
			<td>Dulbecco&#39;s Modified Eagle Medium&#160;</td>
			<td>Gibco&#160;</td>
			<td>C11995500BT&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>EDTA</td>
			<td>Sigma</td>
			<td>EDS-500g&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>FACS tubes</td>
			<td>BD Falcon</td>
			<td>352052</td>
			<td></td>
		</tr>
		<tr>
			<td>fetal bovine serum&#160;</td>
			<td>Gibco</td>
			<td>10270-106</td>
			<td></td>
		</tr>
		<tr>
			<td>flow cytometer</td>
			<td>BD</td>
			<td>FACSCanto II</td>
			<td></td>
		</tr>
		<tr>
			<td>hemocytometer</td>
			<td>PorLab Scientific</td>
			<td>HM330</td>
			<td></td>
		</tr>
		<tr>
			<td>isoflurane</td>
			<td>RWD life science&#160;</td>
			<td>R510-22-16&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>KHCO3&#160;</td>
			<td>Sangon Biotech&#160;</td>
			<td>A501195-0500&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit, for 633 or 635 nm excitation&#160;</td>
			<td>Life Technologies&#160;</td>
			<td>L10199&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>needle carrier&#160;</td>
			<td>RWD Life Science&#160;</td>
			<td>F31034-14&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>NH4Cl&#160;</td>
			<td>Sangon Biotech</td>
			<td>A501569-0500&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>paraformaldehyde</td>
			<td>Beyotime</td>
			<td>P0099-500ml&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>PE anti-mouse TCR V&#945;2</td>
			<td>BioLegend</td>
			<td>127808</td>
			<td>Clone:B20.1&#160;</td>
		</tr>
		<tr>
			<td>Pen Strep Glutamine (100x)</td>
			<td>Gibco</td>
			<td>10378-016</td>
			<td></td>
		</tr>
		<tr>
			<td>PerCP/Cy5.5 anti-mouse CD8a&#160;</td>
			<td>BioLegend</td>
			<td>100734</td>
			<td>Clone:53-6.7</td>
		</tr>
		<tr>
			<td>RPMI-1640</td>
			<td>Sigma</td>
			<td>R8758-500ML</td>
			<td></td>
		</tr>
		<tr>
			<td>sodium azide</td>
			<td>Sigma</td>
			<td>S2002&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>surgical forceps</td>
			<td>RWD Life Science&#160;</td>
			<td>F12005-10</td>
			<td></td>
		</tr>
		<tr>
			<td>surgical scissors</td>
			<td>RWD Life Science&#160;</td>
			<td>S12003-09&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>suture thread</td>
			<td>RWD Life Science</td>
			<td>F34004-30&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>trypsin-EDTA</td>
			<td>Sigma</td>
			<td>T4049-100ml</td>
			<td></td>
		</tr>
	</tbody>
</table>

draining lymph node metastasis model for assessing the dynamics of antigen-specific cd8+ t cells during tumorigenesis

Tumor antigen-specific CD8+ T cells from draining lymph nodes gain an accumulating importance in mounting anti-tumor immune response during tumorigenesis. However, in many cases, cancer cells form metastatic loci in lymph nodes before further metastasizing to distant organs. To what extent the local and systematic CD8+ T cell responses were influenced by LN metastasis remains obscure. To this end, we set up a murine LN metastasis model combined with a B16F10-GP melanoma cell line expressing the surrogate neoantigen derived from lymphocytic choriomeningitis virus (LCMV), glycoprotein (GP), and P14 transgenic mice harboring T cell receptors (TCRs) specific to GP-derived peptide GP33-41 presented by the class I major histocompatibility complex (MHC) molecule H-2Db. This protocol enables the study of antigen-specific CD8+ T cell responses during LN metastasis. In this protocol, C57BL/6J mice were subcutaneously implanted with B16F10-GP cells, followed by adoptive transfer with naive P14 cells. When the subcutaneous tumor grew to approximately 5 mm in diameter, the primary tumor was excised, and B16F10-GP cells were directly injected into the tumor draining lymph node (TdLN). Then, the dynamics of CD8+ T cells were monitored during the process of LN metastasis. Collectively, this model has provided an approach to precisely investigate the antigen-specific CD8+ T cell immune responses during LN metastasis.

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8&lt;sup&gt;+&lt;/sup&gt; T Cells During LN Metastasis

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis

This protocol provides a useful reproductive model for the studies of antigen specific CD8 T-cells. They are lymph node metastasis, which excludes the participation of bystander CD8 T-cells. We try to reveal the systemic and local dynamics of antigen specific CD8 T cells They are lymph node metastasis.Recent accumulating evidence revealed that tumor specific CD8 T cells derived from the periphery, especially in tumor draining lymph node, but not in tumor microenvironment met the efficacy of immune checkpoint blockage therapy. Recently we identified this in one positive talks negative tumor sub specific memory T cells in tumor draining lymph nodes of both mice tumor models and human hepatocellular carcinoma patients which serve as general responders to immune checkpoint blockage. It is difficult to evaluate the precise time points of intubation because lymph nodes metastasis through other techniques is not always feasible.This protocol has provided an approach to precisely investigate the antigen specific CD8 T-cells immune responses. The lymph node metastasis, which excludes the participation of bystander CD8 T cells. Our experimental design provides a useful model to investigate the antigen specific CD8 T-cells, the lymph node metastasis and interactions between antigen specific CD8 T cells and other immune cells or stroma cells during lymph node metastasis.We'll try to elucidate how lymph node metastasis affects the anti-tumor immune response, especially the properties and the functions of TDR and TTSM cells. This results would affect the clinical treatment options of whether to remove or retain the MLN and show the new light on the manipulation of MLN to achieve maximum therapeutic benefits.

The schematic diagram of this experimental design is shown in Figure 1A. A total of 5 x 105 B16F10-GP cells in 100 &#181;L of PBS were subcutaneously (s.c.) implanted into the bilateral inguinal region of CD45.2 C57BL/6J mice. After 7 days, these tumor-bearing mice were intraperitoneally (i.p.) injected with 4 mg CTX, followed by the adoptive transfer of 5 x 105 CD45.1+P14 cells through tail intravenous (i.v.) injection. When tumors grew to approximately 3-5 ...

Watch this Scientific Journal Video about Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis at JoVE.com

The experimental design presented here provides a useful reproductive model for the studies of antigen-specific CD8+ T cells during lymph node (LN) metastasis, which excludes the perturbation of bystander CD8+ T cells.

Tumor antigen-specific CD8+ T cells from draining lymph nodes gain an accumulating importance in mounting anti-tumor immune response during tumorigenesis. ...

draining-lymph-node-metastasis-model-for-assessing-dynamics-antigen